MariMed Reports First Quarter 2022 Earnings

5.4 min readPublished On: May 10th, 2022By

NORWOOD, Mass. – MariMed, Inc. (OTCQX: MRMD), a multi-state cannabis operator focused on improving lives every day, announced its financial results for the first quarter ended March 31, 2022.

“I am very pleased with our solid financial results this past quarter despite a slowdown in our industry coupled with rising inflation in the U.S.,” said Bob Fireman, Chief Executive Officer of MariMed. “We are executing on our strategic growth plan, as evidenced by the recent closings of both our Maryland and Illinois acquisitions. We will continue delivering on our promises to our shareholders, including maintaining our standing as one of the best stewards of capital in our industry.”

Selected Financial Highlights
Three Months
Ended March 31,
Change (%)
($ in thousands) 2022 2021
Revenues $ 31,282 $ 24,643 27 %
Gross Profit $ 16,976 $ 13,186 29 %
Gross Margin 54.3 % 53.5 %
Operating Expenses $ 9,927 $ 6,148 61 %
Non-GAAP Adj. EBITDA1 $ 10,362 $ 8,033 29 %
Non-GAAP Adj. EBITDA Margin1 33.1 % 32.6 %
Cash Provided By Operations $ 8,490 $ 6,759 26 %
Working Capital $ 20,129 $ 17,390 16 %
1. Please see the reconciliations of non-GAAP financial measure to the most directly comparable GAAP measures in the “Non-GAAP financial measures” section.

MariMed management will host a conference call on Wednesday, May 11, 2022, to discuss these results at 8:00 a.m. Eastern time. The conference call may be accessed through MariMed’s Investor Relations website by clicking the following link: MariMed Q122 Earnings Call.


  • Revenue from retail dispensary operations grew 41% compared to the first quarter of 2021, which was driven by a new dispensary in Metropolis, Illinois, and higher customer counts in both Illinois and Massachusetts.
  • Revenue from wholesale operations grew 6% compared to the first quarter of 2021 as a result of both the increased production from MariMed’s manufacturing facility and the increased number of licensed dispensary clients in Massachusetts.
  • Revenue from licensing, management fees, and real estate income increased 2% compared to the first quarter of 2021 as a result of the continued success of the Company’s award-winning brands that are licensed in seven states and Puerto Rico, as well as growth in the Company’s managed businesses.
  • The Company launched Vibations: High + Energy, entering the fast-growing beverage category with a line of THC-infused powdered drink mixes in Massachusetts.
  • The Company licensed its award-winning portfolio of branded edibles, including Betty’s Eddies, Bubby’s Baked, k Fusion, and Vibations: High + Energy, to its partner in Delaware.

Subsequent to the end of the first quarter 2022, the Company announced the following significant business developments:

  • April 7: The Company announced it filed a preliminary non-offering long-form prospectus in Canada. The Company also intends to apply to list its common shares on the Canadian Securities Exchange (CSE). The Company believes trading on the CSE will increase liquidity for shareholders and provide easier access to Canadian retail and institutional investors, in addition to U.S. investors on the OTCQX market.
  • April 28: The Company announced it closed on the acquisition of Kind Therapeutics USA, LLC (“Kind”), a leading vertically integrated cannabis operation in Maryland, that MariMed developed and managed for several years. The Company now operates a cultivation and processing facility in a 180,000 square foot industrial building in Hagerstown and plans to open and operate a medical dispensary in Annapolis later this summer.
  • May 5: The Company announced it closed on the acquisition of a craft cannabis license in Illinois, enabling MariMed to become fully vertical in this high-growth state. Construction of a new cultivation and processing facility in Mount Vernon, Illinois is underway. When completed, the Company expects to sell its portfolio of award-winning brands in its four Thrive dispensaries and into the Illinois wholesale marketplace. The Company expects this will lead to increased revenue and gross margins in Illinois beginning in late 2022.

The Company maintained its previous financial guidance for fiscal year 2022, including:

  • Revenue of $145 million to $150 million.
  • Gross margin in line with fiscal 2021 gross margin of 54% to 55%
  • Non-GAAP Adjusted EBITDA of $47 million to $52 million.
  • Capital Expenditures of approximately $25 million.

“We ended the first quarter with a cash balance of $33.5M and generated positive cash flow from operations of $8.5 million. Our strong first quarter financials during an industry-wide slowdown, gives us confidence we will meet or beat our financial guidance for 2022,” said Jon Levine, Chief Financial Officer of MariMed.

The table below reconciles Net Income to Adjusted EBITDA:

Three Months Ended
March 31,
($ in thousands) 2022 2021
Net income $ 4,241 $ 4,310
Interest expense, net 150 1,478
Income taxes 3,660 1,204
Depreciation and amortization 842 639
Non-GAAP EBITDA 8,893 7,631
Stock Based Compensation 2,471 300
Amortization of warrant issuances 56
Loss on equity Issued to settle Obligations 1
Gain (loss) on change in fair value of investment (48 ) 45
Other investment income (954 )
Non-GAAP Adj. EBITDA $ 10,362 $ 8,033

The Company has provided in this release non-GAAP Adjusted EBITDA as a supplement to Revenues, Gross Profit, and other financial measures prepared in accordance with GAAP.

Management defines non-GAAP Adjusted EBITDA as net income, determined in accordance with GAAP, excluding the following items:

  • interest income and interest expense;
  • income taxes;
  • depreciation of fixed assets and amortization of intangible assets;
  • non-cash expenses on debt and equity issuances;
  • impairment or write-downs of intangible assets;
  • unrealized gains and losses on investments and currency translations;
  • legal settlements;
  • gains or losses from the extinguishment of debt via the issuance of equity;
  • discontinued operations; and
  • merger- and acquisition-related transaction expenses.

Management believes Non-GAAP Adjusted EBITDA is a useful measure to assess the performance of the Company as it provides meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses Adjusted EBITDA to understand and compare operating results across accounting periods, and for financial and operational decision making. The presentation of non-GAAP Adjusted EBITDA is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP Adjusted EBITDA in assessing the Company’s financial results and its ongoing business as it allows for meaningful comparisons and analysis of trends in the business. Non-GAAP Adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP measurements, the Company’s calculations may differ from those used by analysts, investors, and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

(This information is primarily sourced from MariMed Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • Financial Result, CBD Skin Care Market, Cannabis Testing Market

Global Cannabis Testing Market Analysis Report 2023-2030

February 4th, 2023|

DUBLIN - Global Cannabis Testing Market to Reach $2.8 Billion by 2030 In the changed post COVID-19 business landscape, the global market for Cannabis Testing estimated at US$1.1 Billion in the year 2022, is projected to reach ...